Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma

被引：0
|
作者：
Yu-Yun Shao [1 ]
Han-Yu Wang [3 ]
Hung-Wei Hsu [4 ]
Rita Robin Wo [3 ]
Ann-Lii Cheng [3 ]
Chih-Hung Hsu [3 ]
机构：
[1] National Taiwan University College of Medicine,Graduate Institute of Oncology
[2] National Taiwan University College of Medicine,Department of Internal Medicine
[3] National Taiwan University Hospital,Department of Oncology
[4] National Taiwan University Cancer Center,Department of Medical Oncology
来源：
Biology Direct | / 20卷 / 1期
关键词：
Beta-catenin; Hepatocellular carcinoma; Immunotherapy; Programmed death-ligand 1; Tankyrase; Wnt pathway;
D O I：
10.1186/s13062-025-00645-8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
    Lin, Heng
    Wei, Shuang
    Hurt, Elaine M.
    Green, Michael D.
    Zhao, Lili
    Vatan, Linda
    Szeliga, Wojciech
    Herbst, Ronald
    Harms, Paul W.
    Fecher, Leslie A.
    Vats, Pankaj
    Chinnaiyan, Arul M.
    Lao, Christopher D.
    Lawrence, Theodore S.
    Wicha, Max
    Hamanishi, Junzo
    Mandai, Masaki
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (02): : 805 - 815
  • [32] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [33] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Rosemarie Tremblay-LeMay
    Nasrin Rastgoo
    Hong Chang
    Journal of Hematology & Oncology, 11
  • [34] The PD-1/PD-L1 Pathway in Human Pathology
    Saresella, M.
    Rainone, V.
    Al-Daghri, N. M.
    Clerici, M.
    Trabattoni, D.
    CURRENT MOLECULAR MEDICINE, 2012, 12 (03) : 259 - 267
  • [35] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Tremblay-LeMay, Rosemarie
    Rastgoo, Nasrin
    Chang, Hong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [36] Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
    Wang, Zhijie
    Yuan, Lin
    Liao, Xiaotong
    Guo, Xia
    Chen, Jianjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) : 6027 - 6043
  • [37] PD-1/PD-L1 Pathway in Breast Cancer
    Schuetz, Florian
    Stefanovic, Stefan
    Mayer, Luisa
    von Au, Alexandra
    Domschke, Christoph
    Sohn, Christof
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 294 - 297
  • [38] Biomarkers of response to PD-1/PD-L1 inhibition
    Vareki, Saman Maleki
    Garrigos, Carmen
    Duran, Ignacio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
  • [39] Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
    Gong, Xue-Qin
    Liu, Ning
    Tao, Yun-Yun
    Li, Li
    Li, Zu-Mao
    Yang, Lin
    Zhang, Xiao-Ming
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [40] Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
    Sakakida, T.
    Ishikawa, T.
    Chihara, Y.
    Harita, S.
    Uchino, J.
    Tabuchi, Y.
    Komori, S.
    Asai, J.
    Narukawa, T.
    Arai, A.
    Tsunezuka, H.
    Kosuga, T.
    Konishi, H.
    Moriguchi, M.
    Yasuda, H.
    Hongo, F.
    Inoue, M.
    Hirano, S.
    Ukimura, O.
    Itoh, Y.
    Taguchi, T.
    Takayama, K.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06): : 919 - 927
12345